Clinical trial NCT01190150: Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding
Official title: Randomized, 2-way Crossover, Pharmacokinetic Study of Lysteda (Xanodyne Modified-Immediate Release Tranexamic Acid) Tablets at 2 Doses in Fasting Adolescent Females With Evidence of Heavy Menstrual Bleeding
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Menorrhagia
Keywords: Cyclic Heavy Menstrual Bleed
Menorraghia
Lead sponsor: Ferring Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2010-08-27
Enrollment: 20
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: This is a Phase 4, randomized, 2-way crossover, pharmacokinetic study of Lysteda (tranexamic acid) tablets administered as single doses of 0.65 g and 1.3 g in fasting adolescent female subjects ages 12-16 years with heavy menstrual bleeding.


Eligibility criteria: Inclusion Criteria:

* Generally healthy non-smoking (for at least 3 months) adolescent females 12-16 years of age with a history of at least 1 year of cyclic heavy menstrual bleeding (HMB)
* Subjects must report regularly occurring menstrual periods ≤10 days in duration, with 21-45 days from the start of one period to the start of the next menstrual period
* Diagnosis of HMB based on the medical judgment of the Principal Investigator and will include the following criteria:

  1. Laboratory (including a bleeding disorders work-up) and Physical Findings;
  2. Limitations in Activities of Daily Living (ADL);
  3. Soiling, Staining and Clotting;
  4. Sanitary product usage and extent of MBL using a patient reported pictorial blood assessment chart (PBAC).
* Subjects should either be sexually inactive (abstinent) or be using one of the following acceptable birth control methods and agree to continue its use throughout the study:

  * copper intrauterine device (IUD) in place for at least 3 months;
  * barrier methods (condom, diaphragm) with spermicide for at least 1 month prior to the first dose and throughout the study.
* Negative pregnancy test results
* Subject's legally authorized representative (e.g., parent, guardian) must voluntarily sign a parental permission/informed consent form (ICF), and the subject must sign an assent, before the conduct of any study procedure

Exclusion Criteria:

* Breast-feeding, or a history of abortion in the last 6 months
* Known bleeding or coagulation disorders based on medical history and/or laboratory results
* Known systemic hematologic diseases (e.g., all types of sickle-cell disease, thalassemia of all types, multiple myeloma, hemolytic anemia)
* Clinical evidence of any significant chronic illness, including cardiovascular, renal, neurologic, hepatic, endocrine, gastric, central nervous system disease, any psychiatric illness which could affect the efficacy or safety of study medication
* Subjects treated with systemic steroids in the last 1 month or hormonal treatment in the last 3 months
* A history or presence of any drug abuse or alcohol abuse within the last 1 year
* History of subarachnoid hemorrhage.
* Active thromboembolic disease; history of thrombosis or thromboembolism, including retinal vein or artery occlusion; an intrinsic risk of thrombosis or thromboembolism
* Use of vaginal hormone products (rings, creams, and gels) within 4 weeks prior to screening. Use of oral estrogen-, progestin-, or selective estrogen receptor within 8 weeks prior to screening. Use of Lupron (3-month depot injection), estrogen pellet, or long-acting progestin injectables within 6 months prior to screening
* Subjects whose sitting blood pressure is less than 90/60 mmHg at screening
* Subjects whose pulse is lower than 50 b.p.m. at screening
* Subjects whose PR interval is \>200 msec at screening and prior to dosing
* Subjects whose QTc interval \>450 msec
* Subjects with positive tests for hepatitis B, C, or human immunodeficiency virus (HIV)

Primary outcomes:
measure: Maximum Concentrations Level (Cmax)
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
measure: Dose-normalized Maximum Concentrations Level (Cmax)
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
measure: Time to Maximum Concentration Level (Tmax)
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
measure: Area Under the Concentration Versus Time Curve From 0 to the Last Time Point (AUC0-t)
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
measure: Dose Normalized Area Under the Concentration Versus Time Curve From 0 to the Last Time Point (AUC0-t)
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
measure: Area Under the Concentration Versus Time Curve From 0 to Infinity (AUCinf)
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
measure: Dose Normalized Area Under the Concentration Versus Time Curve From 0 to Infinity (AUCinf)
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
measure: The Ratio of AUC0-t to AUCinf
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
measure: Elimination Half-life (t ½)
timeFrame: Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)
Secondary outcomes:
measure: Participants With Treatment-emergent Adverse Events (TEAEs)
timeFrame: Day 1 up to week 4
Other outcomes:
Locations:
city: Cypress
country: United States
facility: West Coast Clinical Trials
state: California
Study officials:
affiliation: Ferring Pharmaceuticals
name: Clinical Development Support
role: STUDY_DIRECTOR
References: